Hope Rugo, MD
The role of immunotherapy is slated to become more refined in triple-negative breast cancer (TNBC), as phase III data showcasing the combination of a checkpoint inhibitor with chemotherapy are eagerly awaited, explained Hope S. Rugo, MD.
on Breast Cancer, Rugo, professor of medicine, director of the Breast Oncology Clinical Trials Program, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discussed the highly anticipated studies of immunotherapy in TNBC and where the class of agents optimally fits in the landscape.
OncLive®: How would you describe the state of immunotherapy in TNBC?
: It is actually a really exciting area where we are learning more and more about predictors of response. It is enhanced by the recent press release for data that will be presented at the 2018 ESMO Congress from the IMpassion130 study. This trial looked at nab-paclitaxel as first-line chemotherapy for metastatic TNBC with either the checkpoint inhibitor atezolizumab or placebo. It was reported in the press release that it met its primary endpoint in terms of progression-free survival (PFS), and it was also reported that there were encouraging overall survival (OS) results in the overall population and in the PD-L1–positive subset. These are actually very exciting data that we expect to lead to the first checkpoint inhibitor approval for breast cancer.
... to read the full story